Children

PediCAP trial findings disseminated to Mozambican healthcare community

2024

The PediCAP trial team is pleased to announce the successful completion of a series of dissemination meetings aimed at sharing trial results with key stakeholders in Mozambique. These meetings targeted a diverse audience, including healthcare professionals, paediatricians, collaborators, policymakers and representatives from the National Bioethics Committee (CNBS) and the National Regulatory Authority for Medicines and Pharmacovigilance (ANARME).

The dissemination efforts commenced at the Universidade Eduardo Mondlane Faculty of Medicine,

Read More

Four-day antibiotic treatment shows promise for childhood pneumonia in Africa

2024

The PediCAP consortium, a global partnership of 14 institutions, presented promising results from its main trial, PediCAP-A, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) conference held from April 27-30, 2024, in Barcelona, Spain. This research introduces a more child-centred  approach to managing severe community-acquired pneumonia (CAP), a leading cause of hospitalisation and death in children in resource limited settings.

Currently, the World Health Organization recommends treating severe CAP with injectable antibiotics for five days,

Read More

Future-proofing children’s health through immunisation  

2024

This World Immunisation Week, Penta – Child Health Research proudly recognises 50 years of progress in child immunisation and the power of vaccines in protecting preventable diseases. Vaccination programs worldwide have saved millions of children’s lives and continue to be a powerful tool for promoting global health equity. 

However, despite the undeniable benefits of vaccines for children, a concerning gap exists. Vaccines for children often lag behind adult vaccines due to a smaller market size,

Read More

The UNIVERSAL project’s potential impact on the health of children living with HIV, told by Dr Vivian Mumbiro

2023

In recent years, advancements in medical research have paved the way for an array of treatment options for children living with HIV. The efforts of scientists and researchers globally, have led to continuous refinement and improvement of existing regimens. Dr. Vivian Mumbiro, affectionately known as Dr V, a dedicated Medical Officer at the University of Zimbabwe Clinical Research Centre, shares insights into the evolving landscape of paediatric HIV treatment.

Read More

SMILE once-daily regimen non-inferior to triple ART regimen

2023

Findings from the Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (PENTA-17) trial, simply known as SMILE, were published in eClinicalMedicine on 2 June 2023. SMILE is the first randomised trial to determine whether children living with HIV on ART with suppressed viral load could maintain the suppression on a once-daily regimen compared to the standard of care (SOC) which involves three ART drugs. 

Read More

World AIDS Day 2022: Is HIV cure attainable in our lifetime?

2022

In the lead-up to #WorldAIDSDay2022, people wonder, is an HIV cure attainable in our lifetime?

Yes, we believe there are good reasons to be optimistic about a cure:

  • The advances in treatment
  • Better access to therapy
  • Early initiation of effective antiretroviral treatment
  • Increasing numbers of children living with HIV who are surviving into adolescence and beyond
  • Reported cases of people living with HIV with a viral reservoir to a level that allowed maintenance of remission even after treatment interruption.
Read More

Penta investigates cases of acute hepatitis of unknown origin in children

2022

On 12 May, a Rapid Communication on the reported increase of acute hepatitis of unknown origin in children was published in Eurosurveillance. The paper outlines the extent and geographical distribution of these unexplained paediatric hepatitis cases in Europe and beyond. It also highlights the challenges of drawing comparisons against a baseline of a syndrome which is not under systematic surveillance and has no standard case definitions in place.

Read More

🇬🇧 VERDI project launches

2021

Today we launch VERDI, a project that prioritizes women and children in the research on new coronavirus variants

The University of Padua and Penta Foundation are leaders of VERDI, a new European research consortium on coronavirus in children and pregnant women. Carlo Giaquinto, Professor at University of Padova and President of Penta, together with Professor Ali Judd at University College London, will be the scientific coordinators of VERDI.

 

Read More

World Pneumonia Day 2021: Every breath counts

2021

It’s impossible to ignore the Covid-19 pandemic and how it has gripped the lives of everyone around the world, but it is equally impossible to ignore the thousands of lives that are lost daily to chest infections (pneumonia). According to UNICEF, pneumonia is the single largest cause of death in children under five and the majority of these deaths occur in low- and middle-income countries.

Pneumonia needn’t be the deadly infectious disease that it is today.

Read More

ODYSSEY trial wins 2021 Hector Award

2021

It was announced at the 8th European AIDS Conference that Angela Colbers and David Burger received the Hector Research Award in HIV 2021 in clinical and/or epidemiological science on behalf of the ODYSSEY trial team!

The winning paper Simplified dolutegravir dosing for children with HIV weighting 20kg or more pharmacokinetic and safety substudies of the multicentre randomised ODYSSEY trial, can be found here.

Read More

CARMA study publishes article in Journal of International AIDS Society

2021

The CARMA team in the EPIICAL consortium have just published the article Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort) in the Journal of International AIDS Society.

HIV infection causes pathological changes in the natural killer cell compartment, a type of white blood cell with enzymes that kill cells infected with a virus.

Read More

Sharing our understanding of the immune response of children living with HIV

2021

EPIICAL is proud to have presented four abstracts at the CROI conference this year, sharing updated information on viral decay and the immune response of children living with HIV who begin treatment early in life.

 

  • EFFECT OF HIV ON IMMUNE ACTIVATION AND EXHAUSTION IN CD4 AND CD8 T CELLS IN INFANTS Stefano Rinaldi, Vinh B. Dinh, Suresh Pallikkuth, Lesley D.
Read More

ODYSSEY trial finds new drug is better for treating children living with HIV

2021

The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections.

Dolutegravir has a number of potential advantages, including:

  • Few drug-to-drug interactions, making it easier to use when treating people who need treatment for other conditions such as tuberculosis
  • High potency at a low milligram dose,
Read More

Johnson & Johnson has planned trials of its vaccine that will include infants.

2021

Johnson & Johnson plans to test its coronavirus vaccine in infants and even in newborns, as well as in pregnant women and in people who have compromised immune systems.

The bold plan for expanded clinical trials met with the approval of Dr. Ofer Levy, director of the Precision Vaccines Program at Harvard’s Boston Children’s Hospital and a member of the Food and Drug Administration advisory committee that reviewed the company’s vaccine data.

Read More

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

2021

Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al, ODYSSEY trial team

Published in: BMC Infectious Diseases

 

Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents.

Read More

EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir

2021

On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part, on data from our ODYSSEY trial, which we are conducting in close collaboration with the MRC CTU at the University College London.

The EMA also authorised updating dosing recommendations for dolutegravir film-coated tablets (10mg, 25mg and 50mg) for children six years and older and weighing at least 14kg,

Read More

Why schools probably aren’t COVID hotspots

2021

Data gathered worldwide are increasingly suggesting that schools are not hotspots for coronavirus infections. Despite fears, COVID-19 infections did not surge when schools and day-care centres reopened after pandemic lockdowns eased. And when outbreaks do occur, they mostly result in only a small number of people becoming ill.

However, research also shows that children can catch the virus and shed viral particles, and older children are more likely than very young kids to pass it on to others.

Read More

Human Rights Day

2019

Today we celebrate Human’s Right Day: this year’s theme is “Youth Standing Up for Human Rights”.
School HIV-prevention campaigns in Africa are often designed to frighten children. However, we believe this should be done differently. By providing children with information about HIV we can help prevent fear and ensure children are educated.

Peer-support groups play an important role in providing children and adolescents with information they need about HIV.

Read More
1 2